Isoprinosine in the treatment of children with frequent
respiratory tract infections and minor T-lymphocyte
immunodeficiency

J 1999

Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency

LITZMAN, Jiří, Marcela KREJČÍ, Sáva PEŠÁK a Jindřich LOKAJ

Základní údaje

Originální název

Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency

Autoři

LITZMAN, Jiří (203 Česká republika, garant), Marcela KREJČÍ, Sáva PEŠÁK (203 Česká republika) a Jindřich LOKAJ (203 Česká republika)

Vydání

Scripta Medica (Brno), Brno, LF MU Brno, 1999, 1211-3395

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30209 Paediatrics

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/99:00003614

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

inosine pranobex; immunodeficiency; immunotherapy

Štítky

immunodeficiency, Immunotherapy, Inosine pranobex

Změněno: 22. 6. 2009 16:09, prof. MUDr. Jiří Litzman, CSc.

Anotace

V originále

Isoprinosine is a T-lymphocyte enhancing agent sometimes recommended for the treatment of patients with T-lymphocyte deficiency and clinical signs of immunodeficiency. We performed a double-blind trial of treatment of children aged 4-8 years with frequent respiratory tract infection and laboratory signs of T-lymphocyte deficiency - decreased absolute or relative numbers of E-rosette forming cells, CD3+ and CD4+ lymphocytes or increased numbers of CD8+ cells. Thirty two children that finished the study were given isoprinosine and 25 placebo. We could not show any clinical benefit of the administration of isoprinosine on the frequency or severity of respiratory tract infections compared to placebo. An increase in the number of E-rosette forming cells, CD4+ and CD3+ lymphocytes was observed after 6 weeks of isoprinosine administration, but similar, although not significant, changes were observed in the placebo treated group.

Návaznosti

NI4703, projekt VaV

Název: Poruchy imunoregulace u nemocných s humorálními imunodeficity

Investor: Ministerstvo zdravotnictví ČR, Poruchy imunoregulace u nemocných s humorálními imunodeficity

Citovat

LITZMAN, Jiří, Marcela KREJČÍ, Sáva PEŠÁK a Jindřich LOKAJ. Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency. Scripta Medica (Brno). Brno: LF MU Brno, 1999, roč. 72, č. 4, s. 115-124. ISSN 1211-3395.

@article{226532,
   author = {Litzman, Jiří and Krejčí, Marcela and Pešák, Sáva and Lokaj, Jindřich},
   article_location = {Brno},
   article_number = {4},
   keywords = {inosine pranobex; immunodeficiency; immunotherapy},
   language = {eng},
   issn = {1211-3395},
   journal = {Scripta Medica (Brno)},
   title = {Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency},
   volume = {72},
   year = {1999}
}

TY  - JOUR
ID  - 226532
AU  - Litzman, Jiří - Krejčí, Marcela - Pešák, Sáva - Lokaj, Jindřich
PY  - 1999
TI  - Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency
JF  - Scripta Medica (Brno)
VL  - 72
IS  - 4
SP  - 115
EP  - 115
PB  - LF MU Brno
SN  - 12113395
KW  - inosine pranobex
KW  - immunodeficiency
KW  - immunotherapy
N2  - Isoprinosine is a T-lymphocyte enhancing agent sometimes recommended for the treatment of patients with T-lymphocyte deficiency and clinical signs of immunodeficiency. We performed a double-blind trial of treatment of children aged 4-8 years with frequent respiratory tract infection and laboratory signs of T-lymphocyte deficiency - decreased absolute or relative numbers of E-rosette forming cells, CD3+ and CD4+ lymphocytes or increased numbers of CD8+ cells. Thirty two children that finished the study were given isoprinosine and 25 placebo. We could not show any clinical benefit of the administration of isoprinosine on the frequency or severity of respiratory tract infections compared to placebo. An increase in the number of E-rosette forming cells, CD4+ and CD3+ lymphocytes was observed after 6 weeks of isoprinosine administration, but similar, although not significant, changes were observed in the placebo treated group.
ER  -

LITZMAN, Jiří, Marcela KREJČÍ, Sáva PEŠÁK a Jindřich LOKAJ. Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency. \textit{Scripta Medica (Brno)}. Brno: LF MU Brno, 1999, roč.~72, č.~4, s.~115-124. ISSN~1211-3395.

Podrobný výpis o publikaci